Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Update

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 108,500 shares, a decline of 18.5% from the December 15th total of 133,100 shares. Based on an average daily trading volume, of 24,000 shares, the short-interest ratio is currently 4.5 days. Currently, 7.9% of the shares of the company are sold short.

Alaunos Therapeutics Stock Down 2.8 %

Shares of NASDAQ:TCRT opened at $1.73 on Friday. The firm has a 50-day simple moving average of $2.10 and a 200 day simple moving average of $2.84. Alaunos Therapeutics has a fifty-two week low of $1.63 and a fifty-two week high of $32.85.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.